Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
10
×
boston top stories
life sciences
national blog main
national top stories
new york blog main
10
×
new york top stories
biotech
san francisco blog main
clinical trials
san diego blog main
san francisco top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
inclisiran
regeneron pharmaceuticals
alnylam pharmaceuticals
cancer
cholesterol
fda
new york
novartis
pcsk9
praluent
repatha
What
drug
10
×
cholesterol
fda
medicines
lowering
market
medco
new
bio
brings
ceo
long
medicine
patients
plan
pricing
roundup
therapeutics
twice
wave
week
aces
acquire
acquisitions
advantages
agency
ago
agreed
aimmune
allergy
anathema
announced
approval
approved
awaited
awarded
bar
big
biggest
billion
Language
unset
10
×
Current search:
unset
×
" new york blog main "
×
drug
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)